Inhibition of Renin-angiotensin System and Clinical Outcomes of COVID-19

Background and Aim: COVID-19 is an acute respiratory illness caused by the severe syndrome coronavirus 2 (SARS-CoV-2). A few studies with conflicting results have been performed to evaluate relationship between use of angiotensin system inhibitors outcomes. Therefore, this study was compare clinical paraclinical characteristics patients in two groups treated angiotensin-converting enzyme (ACEIs)/angiotensin receptor blockers (ARBs) control group (no history ACEIs/ARBs) Kamkar Shahid Beheshti hospitals Qom City, Iran from March 14, 2019, end September 21, 2020. Materials Methods: This retrospective descriptive reviewing medical record 359 COVID-19, which confirmed a physician via lung scan or reverse transcription polymerase chain reaction (RT-PCR). We used independent t test quantitative variables Chi-square analyze qualitative variables. Results: The common symptoms, number hospitalization days, oxygen saturation, involvement were not significantly different groups. Weakness, nausea, sweating reduced compared ACEIs/ARBs (P<0.05). Regarding biochemical study, patients’ hemoglobin levels lymphocyte count on first day lower than (P<0.05) Conclusion: These findings do provide evidence adverse beneficial effects inhibitors, so we require more detailed larger sample size.